Quest Diagnostics posted Q2 net revenues of USD 3.04 billion, up 10.2% year over year, with reported diluted EPS of USD 2.84, up 15%.
Adjusted diluted EPS under non-GAAP climbed 19.1% to USD 3.12, while reported operating income rose 4.6% to USD 459 million.
Requisition volume increased 13.1%, while revenue per requisition fell 2.8%.
Highlights included double-digit Advanced Diagnostics growth, New York State approval for Haystack MRD, and a larger rollout of lab automation and IntelliDraw.
Full-year guidance was raised to net revenues of USD 11.95 billion-USD 12.05 billion, reported diluted EPS of USD 9.97-USD 10.17.
DGX•
